Vytora Health Review

Vytora Health: the rare telehealth brand that names its pharmacy and its doctors

Most compounded-GLP-1 startups keep two things hidden: which pharmacy actually fills your vials, and which physician group is signing your prescriptions. Vytora Health publishes both on its own site, and that single decision is the strongest reason to consider it. If you want a 50-state platform where you can run semaglutide or tirzepatide at a fair monthly price — and still trade up to FDA-approved brand pens later without switching providers — Vytora is a genuinely sensible pick. The catch is its brand-name pricing, which we'll get to honestly.

How the pricing actually works

Vytora bills by plan length, not by dose, and every plan is all-inclusive: medication, the physician consultation, supplies, free shipping, and ongoing provider support, with no hidden fees layered on at checkout. Compounded semaglutide is a flat monthly rate that drops to $150 a month when you commit to a three-month bundle. Compounded tirzepatide sits higher, in the mid-market range, with its own bundle discount. The bundles save you roughly 17% versus paying month to month, but they bill the full quarter up front — so you're putting more money down to capture the lower per-month figure.

For reference, the category median we track lands around $170 a month, so Vytora's semaglutide is competitive while its tirzepatide is mid-pack rather than a bargain. There's no teaser first-month rate here; the discount comes from bundling, not a promo.

• Best value: compounded semaglutide on the three-month bundle at $150/mo
• Mid-market: compounded tirzepatide — solid, but above the cheapest floor in the category
• Premium: brand-name Mounjaro and Zepbound, priced near retail (see the caveat below)

What you can actually get — compounded, brand, and peptides

This is one of the few platforms carrying both compounded and brand-name options side by side. On the compounded side you get semaglutide and tirzepatide. On the brand side, Vytora can prescribe FDA-approved Mounjaro and Zepbound — useful if you'd rather have the manufacturer's pen than a compounded vial, or if compounded supply tightens. It also offers NAD+ and sermorelin peptides for people exploring those separately, though those sit outside the weight-loss core.

Dosing is clinician-led: a provider escalates your dose over time, and because pricing is flat per drug, a low-dose starter pays the same as someone at a top maintenance dose. That's simple, but it means early-stage patients subsidize the model a little — you're not paying less just because you're on a smaller dose.

The real differentiator: published pharmacy and physician disclosure

Vytora names Vials Pharmacy (Texas) and Greenwich Biosciences as its compounding partners in public — something the large majority of its competitors refuse to do. It also discloses the operating physician group behind the prescriptions: Wasef Health, PC, out of Pinellas Park, Florida, directed by Michael Wasef, MD. For a category where 'who is actually responsible for my care' is usually a black box, being able to look up the pharmacy and the supervising doctor is meaningful transparency, and it's why our editors rate the trust signals here above average.

One honest piece of context: Wasef Health is a multi-brand telehealth physician group that also prescribes for several other unrelated DTC platforms. We verified its physicians' licenses as active and found no shared pharmacy or corporate overlap with Vytora itself — this is the normal 'moonlighting clinical-services group' pattern, not a red flag, but it's worth knowing the doctors aren't exclusive to Vytora.

Coverage and compliance

Vytora operates in all 50 states plus Washington, DC, and it actually spells out how visits work state by state — video where required, audio-only where that's permitted (Kansas, Louisiana, Mississippi, New Mexico, and West Virginia). It carries LegitScript Approved status and is HIPAA compliant, both displayed publicly. There are no FDA warning letters on file for Vytora in our records, which keeps its safety profile clean as of our last review.

Where it falls short

The brand-name option is the weak spot. Mounjaro and Zepbound through Vytora are priced near full retail — well over a thousand dollars a month — which means most patients who want the real pens would do better buying direct from the manufacturer's self-pay program, where the same brands often run a few hundred dollars a month. Treat Vytora's brand offering as a convenience for staying on one platform, not as a way to save money.

• Brand pricing is near retail — manufacturer self-pay programs usually beat it by hundreds a month
• Compounded tirzepatide is mid-market, not the cheapest available
• Flat per-drug pricing means low-dose patients pay the same as high-dose patients
• Bundles bill the full quarter up front to unlock the lower monthly rate
• Per-prescriber state licensing detail is limited, even though the clinical group is named

Who should choose Vytora — and who should skip it

Choose Vytora if transparency is your priority: you want to know your pharmacy and your physician group by name, you value all-inclusive pricing with no surprise fees, and you want the flexibility to move between compounded and brand-name later. It's also a strong fit if you live in a state other providers don't reach, given the full 50-state-plus-DC footprint.

Skip it if your only goal is the rock-bottom price on compounded tirzepatide, or if you specifically want brand-name pens cheaply — in both cases another route will cost you less. You can see how we weigh price, transparency, and oversight on our scoring methodology page.

Bottom line

Vytora Health earns its place by doing what most of the category won't: telling you who fills your prescription and who prescribes it, in plain sight, across every state. Its compounded semaglutide is well-priced, its all-inclusive billing is refreshingly free of nickel-and-dime fees, and its trust signals are solid. Just go in clear-eyed that the brand-name pens are a premium-priced convenience, and the tirzepatide is fair rather than cheap. For transparency-minded patients, that's a trade worth making.

If you're weighing alternatives, Maximus ($149.99/month) and bmiMD ($99/month) are among the closest options we track to Vytora Health.